Submit Manuscript  

Article Details


Pharmacological Therapy of Abdominal Aortic Aneurysm: An Update

[ Vol. 16 , Issue. 2 ]

Author(s):

Yi-dong Wang, Zhen-jie Liu, Jun Ren and Mei-Xiang Xiang*   Pages 114 - 124 ( 11 )

Abstract:


Background: Abdominal aortic aneurysm (AAA), a progressive segmental abdominal aortic dilation, is associated with high mortality. AAA is characterized by inflammation, smooth muscle cell (SMC) depletion and extracellular matrix (ECM) degradation. Surgical intervention and endovascular therapy are recommended to prevent rupture of large AAAs. Unfortunately, there is no reliable pharmacological agent available to limit AAA expansion. In the past decades, extensive investigations and a body of ongoing clinical trials aimed at defining potent treatments to inhibit and even regress AAA growth.

Conclusion: In this review, we summarized recent progress of potential strategies, particularly macrolides, tetracyclines, statins, angiotensin converting enzyme inhibitors, angiotensin receptor blocker, corticosteroid, anti-platelet drugs and mast cell stabilizers. We also consider recently identified novel molecular targets, which have potential to be translated into clinical practice in the future.

Keywords:

Abdominal aortic aneurysm, clinical trials, medical treatment, pharmacological therapy, molecular target, disease.

Affiliation:

Department of Cardiology, Second Affiliated Hospital of Zhejiang University School of Medicine, Cardiovascular Key Lab of Zhejiang Province, #88 Jiefang Road, Hangzhou, Zhejiang, 310009, Department of Vascular Surgery, Second Affiliated Hospital of Zhejiang University School of Medicine, #88 Jiefang Road, Hangzhou, Zhejiang, 310009, Department of Surgery, University of Wisconsin - Madison, Madison, WI, Department of Cardiology, Second Affiliated Hospital of Zhejiang University School of Medicine, Cardiovascular Key Lab of Zhejiang Province, #88 Jiefang Road, Hangzhou, Zhejiang, 310009

Graphical Abstract:



Read Full-Text article